Study of a targeted medicine for certain relapsed leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1/2 trial tests bleximenib, a targeted medicine, for people whose acute leukemia has specific gene changes and has come back or does not respond to treatment. It may help by attacking these leukemia-specific targets when other treatment options have run out.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsed or refractory acute leukemia, meaning it came back or did not improve with standard treatment
- Your leukemia must have one of these gene changes: KMT2A, NPM1, NUP98, or NUP214
- Your age fits the study: children 2 to under 18 for the pediatric part, and adults 18+ for the adult part
- Blood and kidney tests must be within allowed ranges before starting treatment
- Your heart rhythm test (QTc) must be within allowed limits, and you cannot have Long QT syndrome in your family
- You must not have certain leukemia types or major exclusions like active brain/spinal cord (CNS) disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
This trial adds an experimental drug called bleximenib to the usual chemotherapy for people newly diagnosed with AML who have certain genetic changes (NPM1 or KMT2A). The goal is to see if adding this drug helps the treatment work better.
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
This trial tests whether adding a new drug called ziftomenib to standard chemotherapy can help children whose leukemia has come back or not responded to treatment. It is for children with certain genetic changes in their leukemia cells.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.